Toleranzia AB is a Swedish biotechnology company that was founded in 2011 as a spin-out from MIVAC Development AB.

Toleranzia has developed a platform technology for treatment of autoimmune diseases. The main project is directed towards myasthenia gravis, a nerve-muscle disease for which there is a large unmet need for improved medical treatment.

In addition to this indication, the platform technology has also been evaluated in type 1 diabetes, rheumatoid arthritis and multiple sclerosis; common autoimmune diseases for which positive treatment effects have been achieved in animal models.

More information about Toleranzia can be found on the company’s home page.